Globally, tuberculosis (TB) still remains a major public health problem. India is a high TB burden
Introduction
The "captain of all these men of death", tuberculosis (TB) has been a scourge of the humankind from time immemorial. Till date, no other disease in history matches the sheer magnitude of the misery inflicted by TB on the human race in terms of morbidity and mortality. The social and economic consequences of TB have had a profound effect on human existence. Historically, even though several other diseases like smallpox and plague have killed millions of people, their reign has been relatively short-lived; TB has been ever present. The inexorable march of time has witnessed the changing face of TB: from an incurable disease to the hype and hope of being an eminently curable one. However, even today TB remains as a formidable foe threatening to annihilate the human race. This review attempts to provide an overview of our understanding of TB, availability of rapid diagnostic tests including imaging modalities and anti-TB drugs and to outline the challenges that lie ahead in TB control.
Historical Background
Since ancient times, there have been references to TB or illnesses resembling TB from several parts of the world from many civilizations. The earliest references to TB can be found in the language Samskritam (Sanskrit). In the ancient Indian scriptures, The Vedas, TB was referred to as Yakshma (meaning wasting disease). Description of a TB-like disease has been documented in ancient Chinese and Arabic literature [1] [2] [3] . In English literature, the word "consumption" (derived from the Latin word consumer) has also been used to describe TB. The word "tuberculosis" appears to have been derived from the Latin word tubercula (meaning "a small lump") 4, 5 .
Fracastorius (1443-1553) believed that TB was contagious. Thomas Willis (1621 -1675 had documented the clinical presentation of consumption in detail in his treatise Pthisiologica. Richard Morton (1637-1698) had described several pathological appearances of TB 2, 4, 6 . John Jacob Manget gave the description of classical miliary TB in 1700 7 . In 1720, Benjamin Marten conjectured that TB could be caused by "certain species of animalcula or wonderfully minute living creatures". In 1865 Jean Antoine Villemin presented his results suggesting that TB was a contagious disease 1, 2 . However, it was Robert Koch who announced the discovery of the tubercle bacillus during the monthly evening meeting of the Berlin Physiological Society on 24 th March 1882 8 . On this day, after thousands of years, Mycobacterium tuberculosis, the organism causing TB finally revealed itself to humans. Commemorating the centenary of this event, since 1982, 24 th March is being celebrated as "World TB Day" world over. Wilhelm Conrad Roentgen's discovery of X-rays, facilitated radiographic visualization of changes caused by TB in a living person. Thus, it was in the early years of 20 th century that basic concepts related to aetiological agent of TB, consequent pathological changes in humans and detection of the organism became established.
Discovery of streptomycin, para-amino salicylic acid (PAS) and the availability of isoniazid ushered in modern era of effective treatment of TB in the mid1940s. With the emergence of 'short-course' treatment cure for TB has become a reality. In the late 1970s, though TB continued to ravage developing countries like India, there was an optimism in the developed world that TB may cease to be a public health problem 1 .
The emergence of the human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS) ended this optimism and fuelled the resurgence of TB worldwide. Recognizing the importance of the impact of TB globally, the World Health Organization (WHO) took an unprecedented step and declared TB to be a "global emergency" in April 1993 8 . The late 1990s also witnessed the resurgence of drug-resistant TB (DR-TB) with multidrug-resistant TB (MDR-TB) emerging as a major threat [9] [10] [11] . The first decade of the 21 st century has been ravaged by extensively drug-resistant TB (XDR-TB) 12 . Recently, concern has been expressed regarding the occurrence of extremely drug-resistant TB (XXDR-TB) 13, 14 , super XDR-TB 15 , totally drug-resistant TB (TDR-TB) 15, 16 from some parts of the world. The report on the occurrence of TDR-TB from India 17 has raised concern and consternation 18 . Over the millennia, TB never respected anyone and had treated the rich and poor alike with equal disdain.
Definitions
Certain key definitions concerning clinically important forms of TB, drug-resistant TB are listed in Tables IA  19-37 and IB [9] [10] [11] [12] [13] [14] [15] [16] [31] [32] [33] [34] [35] [36] [37] respectively.
Epidemiology

Global burden of TB
The global burden of TB as described in the 16 th global report on TB published by WHO in 2012 37 is shown in Table IIA ; most of the cases occurred in Asia (59%) and Africa (26%).
Indian scenario
The current estimated TB burden in India is listed in Table IIB 30,37-39 . India has featured among the 22 high TB burden countries; and has accounted for an estimated one quarter (26%) of all TB cases worldwide 30
M/XDR-TB
The results of surveillance data on MDR-TB should be interpreted carefully keeping in mind the fact that globally, less than 4 per cent of new bacteriologicallypositive cases and 6 per cent of previously treated Isolates of M. tuberculosis resistant to any one anti-TB drug (SDR-TB); or two or more anti-TB drugs; but not amounting to MDR-TB (see below)
MDR-TB suspect 11
A patient suspected of drug-resistant tuberculosis, based on RNTCP criteria for submission of specimens for drug-susceptibility testing
MDR-TB 11
Isolates of M. tuberculosis resistant to rifampicin and isoniazid with or without resistance to other anti-TB drugs
Pre-XDR-TB
Isolates of Mycobacterium tuberculosis resistant to isoniazid and rifampicin (i.e., MDR-TB tuberculosis) plus (i) either any fluoroquinolone or an injectable agent, but not both
20
(ii) either any fluoroquinolone or at least one second-line anti-TB drug, but not to both
21
XDR-TB 12
Isolates of Mycobacterium tuberculosis resistant to isoniazid and rifampicin (i.e., MDR-TB tuberculosis) plus any fluoroquinolone and at least 1 of 3 injectable second-line anti-TB drugs, namely, capreomycin, kanamycin, or amikacin XXDR-TB *13,14 Isolates of M. tuberculosis resistant to all first-line and second-line anti-TB drugs available (fluoroquinolones, ethionamide, amikacin, para-aminosalycilic acid, capreomycin, kanamycin, cycloserine) and to additional drugs (rifabutin, clofazimine, dapsone, claritromycin, thiacetazone)
TDR-TB (also called super XDR-TB)* 15,16
Isolates of M.tuberculosis resistant to all first-and second-line licensed anti-TB drugs *A WHO Consultation held in March 2012 36 suggested that "a new definition of resistance beyond XDR-TB is not recommended, given technical difficulties with DST of many anti-TB medicines, the lack of standardized DST methods for several anti-TB drugs (including new investigational drugs) and insufficient evidence to link such DST results to treatment outcomes of patients." While the clinical and operational value of the definitions of MDR-TB and XDR-TB have been fairly evident, standardization of technical requirements for the application of terms, such as, XXDR-TB 13, 14 , super XDR-TB
15
, and TDR-TB 15, 16 , their usefulness and limitations need further clarification [34] [35] [36] and these terms need to be interpreted in the proper perspective. TB, tuberculosis; SDR-TB, single drug-resistant tuberculosis; DR-TB, drug-resistant tuberculosis; MDR-TB, multi-drug-resistant tuberculosis; RNTCP, Revised National Tuberculosis Control Programme; HIV, human immunodeficiency virus; XDR-TB, extensively drug-resistant tuberculosis; XXDR-TB, extremely drug-resistant tuberculosis; TDR-TB, totally drug-resistant tuberculosis. Source: Refs. 9-16, 20, 21, 34-37 cases were tested for MDR-TB in 2011 in accredited laboratories, with particularly low levels of testing in the South-East Asia (where India is located) and Western Pacific regions
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. The recent global epidemiological data on M/XDR-TB are shown in Table IIIA , Fig.s 1A and 1B. XDR-TB has been documented from many parts of the world (Fig. 1C ) 40, 41 .
Indian scenario
Observations from reliable accredited mycobacteriology laboratories from India suggest that the prevalence of MDR-TB is quite low in new TB cases (<3%) compared with previously treated patients (15-30%) [42] [43] [44] [45] (Table IIIB) . The prevalence of XDR-TB in studies published from India where drug-susceptibility (2000) (2001) (2002) (2003) 38 , for the country as a whole, the average annual risk of infection (ARI) computed from estimated prevalence was 1.5%. The ARI showed regional variations and was higher in the northern (1.9%) and western (1.8%) zones compared with the eastern (1.3%) and southern (1%) zones. In a subsequent publication 39 , observations from two rounds of house-based tuberculin surveys conducted 8-9 year apart among children aged 1-9 years in statistically selected clusters during 2000-2003 and 2009-2010 were reported. It was observed that ARI rates declined by respectively 6 and 11.7% per year in the north and west zones; no change was evident in the south and east zones. At the national level, ARI declined by 4.5% per year between 1998 and 2007 39 . ‡ Defined as a person with at least one AFB smear positive by sputum microscopy, or at least one sputum culture positive for M. tuberculosis § Prevalence rate calculated from estimated number of persons with disease in 2000, divided by 2000 population estimate || In a recent study (n=98599), the prevalence of bacillary TB, among persons aged 15 years and above, in Faridabad district of Haryana, in northern India was found to be 126 per 100,000 persons (unpublished observations). TB, tuberculosis; AFB, acid-fast bacilli; GoI, Government of India; HIV, human immunodeficiency virus Source: Refs. 30,37-39 The Central TB Division updates these data annually. The updated information can be accessed from the Revised National Tuberculosis Control Programme annual report of the current year available at the URL: http://tbcindia.nic.in/ Table IIIC 46-53 .
Risk factors
Conventionally several genetic, social, environmental and biological determinants of health have been intuitively recognized by clinicians as risk factors for TB (Table IV) [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] . Some of these risk factors are discussed below.
Genetic factors
Certain key issues should be considered while evaluating genetic susceptibility to TB disease. Susceptibility to TB does not follow a Mendelian pattern and is polygenic and multifactorial. Presence of two different genomes, (of the TB bacillus and the host) and their interaction can have influence on the disease 58 . Several reports have implicated a long list of genes with risk of developing TB (Table IV) 58-61 .
HIV infection
HIV infection and AIDS stand out as the most significant among all the risk-factors for TB and has consistently and significantly altered the incidence rate of TB over the last three decades [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] . The impact of HIV/AIDS has been most profound in HIV prevalence sub-Saharan Africa where a dramatic increase in TB notification rates have been documented concurrent with increasing HIV prevalence. Among persons living with HIV (PLWH) TB can develop at any stage of HIV infection and there is a strong evidence suggesting that a declining CD4+ T-lymphocyte count and high viral load are risk factors for disease, while treatment with highly active antiretroviral therapy (HAART) reduces risk [62] [63] [64] .
HIV infection and MDR-TB:
Even though several institutional outbreaks of MDR-TB among HIVinfected patients drew attention to the problem two decades ago [74] [75] [76] [77] [78] as per currently available evidence [79] [80] [81] , HIV infection per se does not appear to be a risk-factor for MDR-TB.
Diabetes mellitus
The lethal interaction between diabetes mellitus (DM) and TB is being increasingly recognized world over [82] [83] [84] . Epidemiological modelling data suggest that in India, 14.8 per cent of all pulmonary TB cases and 20 per cent of sputum smear-positive cases have DM 84 suggesting that DM substantially contributes to the burden of TB, especially sputum smear-positive pulmonary TB in India.
Use of immunomodulator biologicals
Use of immunomodulator drugs (biologicals) has been associated with the development of fatal TB in rheumatoid arthritis 85, 86 . 460 INDIAN J MED RES, MARCH 2013 47/77 (61%)** * patient had XDR-TB at the time of initial diagnosis † 3 of the 48 patients (6.25%) with XDR-TB were HIV-seropositive ‡ 1 patient had XDR-TB at the time of initial diagnosis; of the 12 patients with pre-XDR-TB at the time of initial diagnosis (defined as ofloxacin/kanamycin resistance), 5 were cured, 3 died, 1 defaulted and 3 failed to respond to treatment, with emergence of XDR-TB; 6 of 91 patients who had initially ofloxacin and kanamycin susceptible organisms developed XDR-TB; all patients with XDR-TB were HIV-seronegative § HIV-seropositive patients were excluded from the study || at the baseline, no patient had XDR-TB; 2 treatment failure patients had developed XDR-TB ¶ of the 194 results available for analysis, 77 patients had MDR-TB ** 3 of the 47 patients with XDR-TB were HIV-seropositive XDR-TB, extensively drug-resistant tuberculosis; HIV, human immunodeficiency virus; MDR-TB, multidrug-resistant tuberculosis; DST, drug susceptibility testing; ND, not described; LJ, Lowenstein-Jensen medium; WHO, World Health Organization; MIC, minimal inhibitory concentration; RR, resistance ratio method; RNTCP, Revised National Tuberculosis Control Programme; CTD, Central TB Division; MoH&FW, Ministry of Health and Family Welfare; GoI, Government of India [65] [66] [67] [68] ; reactivation of latent infection and risk of subsequent episodes of TB from exogenous reinfection 69, 70 . Among persons co-infected with HIV and TB, the estimated annual risk of reactivation is 5 to 8 per cent with a cumulative lifetime risk of 30 per cent or more compared to a cumulative lifetime risk of 5 to 10 per cent observed in HIV-seronegative adult patients 62, 71, 72 . Furthermore, in persons co-infected with HIV and TB, the course of HIV infection is accelerated subsequent to the development of TB. The sites of active TB infection act as epifoci of HIV replication and evolution independent of systemic HIV disease activity has been postulated to be one of the important reasons for accelerated progression of HIV infection 
Tobacco smoking
Data from recent systematic reviews on tobacco smoking and TB suggest that tobacco smokers have about three-fold higher risk of TB than non-smokers; even after adjustment for other factors [87] [88] [89] [90] [91] .
Changing clinical presentation of TB
Natural history of TB
The natural history of TB ( Fig. 2 ) 23, 27, 62, [92] [93] [94] [95] [96] is influenced by several factors, the course being determined by the balance between the host 23, 62, 92. immunity and the virulence of the TB bacillus. This understanding also facilitates identification of areas where interventional strategies can be identified for control of TB.
Atypical clinical presentations
Cryptic miliary TB: Miliary TB that was earlier seen primarily as a disease of children, is being increasingly encountered in adults since the 1970s 23, 27, 28, 97 . Apyrexial presentation with progressive wasting strongly mimicking a metastatic carcinoma (cryptic miliary TB) that has been described especially among older people 23, 27, 28, 98, 99 often used to be diagnosed only at autopsy. This entity is being increasingly diagnosed during life in young immunosuppressed persons presently. This has been possible by the advances in imaging studies and increasing use of interventional procedures to procure tissue for confirming the diagnosis.
Acute lung injury and acute respiratory distress syndrome: TB as a primary cause of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) is also being reported in the recent years especially in areas where TB is highly endemic [100] [101] [102] [103] . Increased awareness regarding this entity among intensivists, invasivists and internists, has resulted in a focused search for TB as the treatable cause in patients presenting with ARDS of obscure aetiology.
TB in patients receiving immunomodulator biologicals:
Data regarding the clinical presentation of TB in patients receiving immunomodulator biological, such as, anti-tumour necrosis factor (anti-TNF) antibodies infliximab, adalimumab, golimumab and certolizumab pegol; and the soluble TNF receptor etanercept are emerging. The rate of TB was three to four-fold higher in patients receiving infliximab and adalimumab than in those receiving etanercept 86 .
Presentation as 'pyrexia of unknown origin':
In areas where the disease is endemic, TB tops the list of aetiological causes of pyrexia of unknown origin (PUO) 104, 105 . Till about two decades ago, clinicians either empirically administered anti-TB treatment or had to resort to invasive surgical procedures such as scalene node biopsy, laparotomy to ascertain the diagnosis. Often, the TB was diagnosed only on post-mortem examination. In patients presenting with PUO, miliary TB 27, 28 , intrathoracic (e.g., paratracheal, mediastinal, hilar) and intraabdominal (e.g., retroperitoneal, porta hepatis) lymph node TB 94, 106 , intestinal, omental and mesenteric, hepatic, splenic TB 107 , vertebral TB (often with paraspinal cold abscess)
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, pelvic ascites 109,110 are important occult locations that are identified as the focus of fever by imaging methods facilitating antemortem diagnosis. Many times, bone marrow aspirate and biopsy smear, mycobacterial culture and molecular test evidence could be the only discernible cause of TB in these patients 62, 94 . Sudden cardiac death: Sudden cardiac death due to TB myocarditis, especially in young persons is increasingly being recognized. This condition is often diagnosed at autopsy and extensive TB infiltration of the myocardium with minimal systemic involvement has been described; occult miliary TB has been implicated as the possible cause of myocarditis 111, 112 . Ante-mortem diagnosis of this condition is now possible with echocardiography, and cardiac magnetic resonance imaging (MRI) 113, 114 .
TB among healthcare workers
Health-care workers (HCWs), who are often in close proximity to patients with TB are at an increased risk of developing TB. It has been estimated that in areas of high TB incidence (>100/100,000 population), the stratified pooled estimates for LTBI and TB incidence rate ratios were 8.4 (95% CI 2.7-14.0%) and 3.7 per cent (95% CI 2.9-4.5), respectively; median estimated population-attributable fraction for TB was as high as 0.4% (115). These figures serve as warning bells, especially with regard to HCWs caring for patients with X/MDR-TB 116 and highlight the need for institution of preventive measures. Further, it has been shown that institution of basic administrative and engineering controls and personal protection measures can be effective in reducing the annual tuberculin skin test (TST) conversion rates in HCWs 117 .
Diagnosis
Latent TB infection
Diagnosis of LTBI has been considered important as a tool for assessing the burden of TB for epidemiological purposes. Because LTBI contributes significantly to the pool of active TB cases later on, its recognition is assuming importance in high-risk groups where there is a potential for instituting treatment for this condition 92 . The tuberculin skin test (TST) and interferon-gamma release assays (IGRAs) have been used as diagnostic tests for the detection of LTBI (Table VA) 118-121 .
In high burden TB countries, neither IGRAs nor TST have been found to be adequate in accurately identifying persons who will benefit from treatment of LTBI with false positivity rates greater than 50 per 
Diagnosis of active TB disease
The current diagnostic and genotyping methods for TB are listed in Table VB 125-141 . Innovations such as use of fluorescent staining, light-emitting diode (LED) based microscopes have helped optimizing the yield of sputum smear examination 126 . Sputum mycobacterial culture is considered to be the 'gold standard' for the diagnosis of TB and it also facilitates DST. However, reliable, periodically accredited facilities for mycobacterial culture and DST are not widely available in TB high burden countries limiting their usefulness. Conventional sputum mycobacterial culture takes 6-8 weeks time and valuable time is lost in establishing the definitive diagnosis. In the 1980s, new semi-automated and automated culture systems based on liquid culture medium became available, such as the BACTEC-TB460 radiometric system (Becton Dickinson, Sparks, MD, USA) and facilitated rapid culture and detection of M. tuberculosis with a turn-around time of about 10 days 127, 129 . For nearly a two decades, this was used for rapid culture and DST. The non-radiometric rapid liquid culture methods like Mycobacteria Growth Indicator Tube (MGIT) and BacT/ALERT (BioMe´rieux) then emerged. In 2007 the WHO endorsed the use of liquid culture assays, DST 129 and rapid speciation (strip speciation) tests that detect a TB-specific antigen from positive liquid or solid cultures to confirm the presence of TB bacillus [Capilia TB; Tauns Laboratories Inc., Shizuoka, Japan] 130 for faster diagnosis of TB and MDR-TB 37 .
The nucleic acid amplification based TB diagnostic tests (NAAT) are based on the amplification of short specific sequences of DNA or RNA of M. tuberculosis complex by PCR and the amplified products are then detected by agarose/acrylamide gel electrophoresis, or by various hybridization methods
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. Several in-house PCR assays and commercial kits have been used for rapid diagnosis of TB.
Integrated automated NAAT, the GeneXpert (Cepheid Inc., Sunnyvale, CA, USA) platform combines automated sample preparation, real-time PCR amplification, identification of M. tuberculosis and detection of rifampicin resistance in less than 120 minutes 142 . GeneXpert has the advantage of being simple to use even in field conditions and appears promising technology for rapid diagnosis of TB. However, this test requires uninterrupted electric power supply and is expensive. This test is being evaluated by Revised National Tuberculosis Control Programme (RNTCP) in field conditions.
Promising results from studies carried out in low-resource countries suggest that loop mediated 
Conventional methods
Ziehl -Neelsen stain 30 minutes -For over a century, sputum smear examination for the detection of AFB in clinical specimens by Ziehl-Neelsen method and LowersteinJensen culture have been used as diagnostic tools for TB. Sputum smear examination is a reliable, reproducible and cost-effective tool for diagnosing patients with TB and monitoring the response to anti-TB treatment. Therefore, sputum smear examination has been extensively used as a diagnostic method in national programmes for TB control progress of treatment especially in developing countries.
LED microscopy Light-emitting diode (LED) microscopy is a low cost method that offers the benefit of fluorescence microscopy without the associated operational requirement of including a dark room and special microscope; may be battery operated
Lowenstein-Jensen culture 6-8 weeks 8-12 weeks Gold standard for the diagnosis of TB and it also facilitates DST Liquid culture, DST (e.g., BACTEC-TB460, MGIT 960, BacT/ALERT); rapid speciation (Capilia  TB) 5-12 days 5-10 days BACTEC-TB460 radiometric system measures radioactive CO 2 liberated during decarboxylation of 14 C labelled substrates. When the inoculum contains live TB bacilli, they utilize the 14 C labelled substrate (palmitic acid) and release 14 CO 2 . The BACTEC instrument quantitatively measures the radioactivity and daily increase in the growth index is directly proportional to the rate and amount of growth in the medium. By adding inhibitory substances to the medium, DST can also be done.
The MGIT was introduced initially as a manual system and subsequently as an automated BACTEC MGIT-960 system (Becton Dickinson, Sparks, MD, USA). This system employs tubes containing enriched Middlebrook 7H9 broth with an oxygen sensitive fluorescent sensor embedded in silicone on the bottom of the tube which, upon consumption of the oxygen by the mycobacteria in the culture medium, fluoresces orange when probed with an UV light
Non-commercial culture methods
MODS
Median time 7 days 7-14 days The MODS assay utilizes a liquid medium which facilitates faster growth of the TB bacillus and thereby aids in the early microscopic visualization of characteristic cord formation using an inverted light microscope. Comparison of growth in drug-containing and drug-free wells, susceptible or resistant strains allows anti-TB DST
Newer solid cultures
Nitrate reductase assay 14-18 days 10 days The nitrate reductase assay is based on the principle of detection of nitrites by the action of nitrate reductase (the Griess method). The accuracy of these methods have been evaluated in systematic reviews and meta-analyses that confirmed their high sensitivity and specificity for detecting DR-TB Cerebrospinal fluid reported sensitivity <59% and specificity >96% for a cut-off value of 8 U/L; in another recent meta-analysis 163 using cut-offs ranging from 5-15.5 IU/l, sensitivity of 0.79 (95% CI 0.75-0.83), and specificity 0.91 (95%CI 0.89-0.93) has been reported. It appears that eventhough CSF-ADA cannot distinguish between bacterial meningitis and TB meningitis, ADA values could be important to improve TBM diagnosis, if bacterial meningitis has been ruled out with certainity; may be useful in countries with low incidence of TB AFB, acid-fast bacilli; L-J, Lowenstein-Jensen; ADA, adenosine deaminase; IFN-γ, interferon-γ; Sen, Sensitivity; Spec, Specificity; CI, confidence intervals isothermal amplification (LAMP) has the potential to be a candidate as a molecular test for the rapid diagnosis of TB in clinical samples 143, 144 . M. tuberculosis produces volatile organic compound (VOC) metabolites in-vitro, and their presence in the breath has been considered to be apparent biomarkers of infection 145, 146 .
Serodiagnostic Tests
A broad range of serodiagnostic tests with a varying degree of reliability, repeatability and concordance have been used for the diagnosis of TB. Since no commercial serological assay could consistently result in an improved outcome, the WHO recently recommended that commercial serological tests should not be used for the diagnosis of pulmonary and extrapulmonary TB
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. This view has been endorsed by the RNTCP of Government of India also 148 .
Diagnosis of extrapulmonary TB (EPTB)
The yield of conventional AFB smear and mycobacterial culture and some commonly used nonconventional tests in the diagnosis of EPTB is shown in Table VI [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] . A focused diagnostic approach, procurement of appropriate body fluid and tissue specimens and subjecting these to a battery of diagnostic tests including culture (and DST where feasible) will enhance the diagnostic yield in EPTB. There is a need to systematically evaluate and establish the utility of recently available newer tests such as GeneXpert to facilitate an early diagnosis and increase the diagnostic yield.
Development of accreditation system, quality assured laboratory network expansion
The eventual goal of controlling and probably eliminating TB hinges on rapidly and correctly identifying all TB cases and ensure that all diagnosed patients receive individualized treatment with anti-TB drugs tailored to the DST profile of the isolates obtained 164 . The ongoing struggle to meet the global target for case detection of diagnosing at least 70 per cent of new smear-positive cases, reflects the yawning gap between the need and the availability of quality assured laboratory infrastructure, especially in developing countries like India. Strengthening the capacity of public-sector laboratory networks, ensuring their accreditation initially and periodically thereafter so that a network of reliable quality assured accredited laboratories is eventually available to take TB control forwards are initial steps in this direction. The Expanding Access to New Diagnostics for TB (EXPAND-TB) project 165 , a collaboration among WHO, the Global Laboratory Initiative (GLI), Foundation for Innovative New Diagnostics (FIND) and the Global Drug Facility (GDF), and funded by UNITAID and other partners aims to improve capacity to diagnose MDR-TB in upgraded laboratory services in 27 countries. In India, The RNTCP has also adopted a rigorous procedure for granting accreditation to culture and DST laboratories both in public and private sectors and medical colleges to provide accurate and reliable services for MDR-TB diagnosis and treatment followup. By 2015, it is expected that universal access to MDR-TB diagnosis and treatment will be made available for all smear positive TB cases under the RNTCP 30 .
Imaging Studies
Imaging modalities such as conventional radiography, ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography CT (PET-CT) have been used to localize the disease, assess the extent of organ involvement and evaluate response to treatment. The chest radiograph is the mainstay of imaging pulmonary TB (Fig. 3A-3E) . However, the chest radiograph can be normal in HIV-infected patients with late HIV disease with active TB disease and in some patients with miliary TB 166, 167 . Ultrasonography helps in detecting pleural effusion and ascites (which may sometimes be loculated), focal lesions in the liver and spleen, cold abscesses, intra-abdominal lymphadenopathy, involvement of other abdominal organs. High resolution CT (HRCT), thin-section multidetector row CT (MDCT) have been helpful in identifying pulmonary and miliary lesions, even in those in whom the chest radiograph is normal and has facilitated more frequent antemortem diagnosis of 'cryptic miliary TB' that was earlier diagnosed only at autopsy. CT of the thorax also allows detection of intrathoracic lymphadenopathy, calcification, pleural, pericardial and vascular lesions (Figs. 3F-3I, 4) . CT and MRI of the brain and CT of the abdomen have also been extensively used to study CNS TB and abdominal TB, respectively (Fig. 5) . Magnetic resonance spectroscopy (MRS) has been found to be useful in patients with intracranial tuberculomas where a characteristic large lipid peak with reduced n-acetyl aspartate peak can be seen. PET-CT using 18 F labelled 2-deoxy-D-glucose (FDG) is helpful in locating, defining the extent of activity of TB at various organ sites (that may sometimes not be clinically discernible) (Fig. 6 ) especially in patients with disseminated TB and assessing the activity of lesions that might persist following anti-TB treatment on follow-up. In patients presenting with PUO with no focal localizing clue, nuclear medicine techniques using gallium-67 citrate, technetium-99m methylene diphosphonte (Fig. 7) , radiolabelled white blood cells, and human immune globulin imaging have been used to identify occult foci of infection especially in the bones. However, these techniques have been relatively nonspecific and have not been able to distinguish bacterial mediated infection from non-bacterial inflammation due to other causes 169 . Recently, the radiopharmaceutical technetium-99m labelled ciprofloxacin ( 99m Tc-CPF) has been developed and shown to localize in high concentrations in bacterial abscesses, and not in areas of sterile inflammation 170, 171 . Though not specific for TB, this technique has been used to localize foci of TB osteomyelitis as well 172 and also assess the adequacy of short-course treatment of TB osteomyelitis 173 .
Procurement of body fluids/tissues for diagnostic testing
Radiographic image guided interventional procedures, biopsy of peripherally accessible lesions (e.g., lymph nodes), endoscopic procedures like laparoscopy, colonoscopy, thoracoscopy, can be used in appropriate settings to procure material for diagnostic testing for TB. Endoscopic interventions, such as, endobronchial ultrasound bronchoscopy (EBUS) and endoscopic oesophageal ultrasound, FNACs, biopsies are useful in situations where patients are sputum smear-negative, are unable to produce sputum, present with intrathoracic (e.g., mediastinal, sub-carinal, hilar) lymphadenopathy to procure tissue. Material thus obtained should be subjected to cytopathological, histopathological, microbiological (including DST) and molecular methods for confirmation of TB diagnosis.
Treatment
Evolution of modern multiple drug treatment
The humankind had to wait for more than 60 years following Robert Koch's momentous announcement of the discovery Mycobacterium tuberculosis for drug(s) that could cure TB to become available (Fig. 8 ) . The first controlled clinical trial in the history of medicine conducted by the British Medical Research Council (BMRC) 179 demonstrated the activity of streptomycin. The BMRC assessed the addition of PAS to streptomycin in a controlled clinical trial 181 which showed a lower rate of clinical deterioration, higher rate of culture conversion, and a lower rate of streptomycin resistance in patients receiving streptomycin plus PAS, suggesting that combination treatment with PAS was helpful in preventing the emergence of drug resistance to streptomycin. The first clinical trial with isoniazid was initiated in 1951 182 . Subsequent studies by BMRC 183, 184 further assessed the utility of using two of the three drugs, namely, streptomycin, isoniazid and PAS in various combinations to treat TB. A later clinical trial by BMRC 185 established the duration of anti-TB treatment that would effectively prevent relapse, to be 18-24 months.
Ethambutol, discovered in 1961 got added to the armamentarium of anti-TB drugs 186 and soon replaced PAS in the standard regimens. In the 1960s seminal research conducted by Wallace Fox and co-workers at the National Institute for Research in Tuberculosis (NIRT), Chennai [then called as Tuberculosis Chemotherapy Centre, Madras; later renamed as Tuberculosis Research Centre (TRC), Madras in 1978] showed that home or ambulatory treatment was almost as effective as sanatorium treatment "provided the regular use of anti-TB medication was well organized and supervised", a fact that is often neglected even the standard treatment duration of anti-TB treatment could be shortened to 9 months. By then the 9-month rifampicin containing regimens replaced the then prevailing standard treatment of 18-months. In 1972, the therapeutic role of pyrazinamide used in a reduced dosage was rediscovered in the studies conducted by East Africa Medical Council and BMRC 193 . Combining pyrazinamide to rifampicin containing regimens then ensued. The 6-month regimens containing rifampicin and pyrazinamide were as effective as either rifampicin or pyrazinamide containing regimens in the clinical trials by the British Thoracic Society 194 heralding the modern 6-month short-course chemotherapy endorsed by the WHO that has become the standard of care worldover. Since then, most countries have been using the WHO endorsed standardized daily or thrice-weekly intermittent treatment regimens in National TB Control Programmes.
National Tuberculosis Programme (NTP)
In 1962, the NTP was started in India, the first time ever a 'national programme' was conceived to tackle the menace of TB in the world. Short-course chemotherapy was introduced in the NTP by 1985. 
Bedaquiline & Delamanid
However, uninterrupted drug supply and treatment adherence continued to plague the NTP and the programme did not make a significant epidemiological impact on the prevalence of TB in the country 195 . This led to introspection and a comprehensive joint review of the TB programme in India by members of several organizations including the Government of India, WHO and Swedish International Development Agency (SIDA) in 1992 identified many issues that were affecting the programme performance 196 .
Revised National Tuberculosis Control Programme
To revamp TB control in India, in 1993, the RNTCP, based on the WHO-recommended DOTS strategy, began operations in five pilot sites. Following pilot testing, large scale expansion of RNTCP in India began in 1997 in a phased manner and by March 24, 2006 , the whole country was covered by the RNTCP. The Programme aims at achieving and maintaining a cure rate of at least 85 per cent among new sputum positive (NSP) patients, and to achieve and maintain case detection of at least 70 per cent of the estimated NSP cases in the community 196, 197 .
Treatment of active TB disease: issues concerning dosing frequency and duration of treatment
The current treatment regimens listed in the recent WHO guidelines for national programmes 29 and the RNTCP of Government of India 30 are shown in Tables   VIIA, VIIB and VIIC. The WHO guidelines 29 suggest that HIV patients co-infected with TB should be treated with daily regimens. This recommendation has been based on evidence from meta-analyses 198, 199 that showed that HIV co-infected patients with pulmonary TB were at a higher risk of acquired rifampicin resistance, when failing a three times weekly shortcourse intermittent regimen. In the meta-analysis 199 of treatment of active TB in HIV co-infected patients, data from six randomized trials and 21 cohort studies showed that compared with daily therapy in the initial phase (n=3352 patients from 35 study arms), thriceweekly therapy (n=211 patients from 5 study arms) was associated with higher rates of treatment failure (adjusted risk ratio, 4.0; 95% CI 1.5-10.4) and relapse (adjusted risk ratio 4.8; 95% CI 1.8-12.8) and a trend toward higher relapse rates if rifamycins were used for only 6 months, compared with 8 months or more, or if antiretroviral therapy was not used. In a study from India 200 the outcome of fully intermittent thriceweekly antituberculosis treatment regimens of 6-month isoniazid, rifampicin, pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampicin; and a 9-month regimen where the intensive phase was same but continuation phase was 7 months, were assessed in HIV-TB co-infected patients. In the 'intentto-treat analysis', among patients who had a favourable outcome at the end of treatment, bacteriologically confirmed recurrence rate was significantly higher * the NTP needs to review country-specific data to verify, or modify, the assignment of treatment failure patients to high likelihood of MDR and patients returning after relapse or default to medium or low likelihood of MDR † ideally DST is done for all patients at the start of treatment so that the most appropriate therapy for each individual can be determined. The guidelines also advocate that patients who remain sputum smear-positive at the end of the intensive phase should submit another specimen for smear microscopy the following month. If that specimen is also smear-positive, culture and DST should be undertaken so that a result will be available earlier than the fifth month of treatment ‡ a country's standard MDR regimen is based on country-specific DST data from similar groups of patients § a temporary measure that can be implemented only if culture and DST can be arranged in the first few months of MDR treatment in each enrolled patient MDR, multidrug-resistance; DST, drug susceptibility testing; DRS, drug-resistance surveillance Source: Ref. 29 Previously treated (Category II) Smear-positive relapse Smear-positive treatment failure Smear-positive treatment after default Others † 2H 3 R 3 Z 3 E 3 S 3 + 1H 3 R 3 Z 3 E 3 + 5H 3 R 3 E 3 * The number before the letters refers to the number of months of treatment. The subscript after the letters refers to the number of doses per week. The dosage strengths are as follows: H = isoniazid (600 mg), R = rifampicin (450 mg), Z = pyrazinamide (1500 mg), E = ethambutol (1200 mg), S = streptomycin (750 mg). Patients who weigh 60 kg or more receive additional rifampicin (150 mg). Patients who are more than 50 years old receive streptomycin (500 mg). Patients who weigh less than 30 kg receive drugs as per body weight. Patients in Categories I and II who have a positive sputum smear at the end of the initial intensive phase receive an additional month of intensive phase treatment Seriously ill also includes any patient, pulmonary or extrapulmonary who is HIV-positive and declares his/her sero-status to the categorizing/treating MO. † In rare and exceptional cases, patients who are sputum smear-negative or who have extra-pulmonary disease can have relapse or failure. This diagnosis in all such cases should always be made by a medical officer and should be supported by culture or histopathological evidence of current, active TB. In these cases, the patient should be categorized as 'Others' and given previously treated (Category II) treatment Source: Ref. 29 with the 6-month regimen compared with the 9-month regimen.
Daily vs thrice-weekly treatment:
Under the RNTCP, in India, 15,852,745 patients have been treated with thrice-weekly intermittent treatment and 2,853,494 lives have been saved 201 reflecting the huge success achieved by the RNTCP programme over the last 15 years. While thrice-weekly intermittent treatment seems adequate in HIV-seronegative patients, use of daily therapy is an important issue to contend with in HIV-seropositive persons. The prospect of considering the implementation of a daily treatment regimen and the logistics of direct observation of treatment are being actively considered and a clear-cut government policy on the same is expected to be available soon. However, head-on comparisons of adequately powered, fully daily, partial daily (daily intensive phase and thriceweekly intermittent continuation phase) and fully thrice-weekly intermittent regimens are not available in the literature and studies of this nature will help in arriving at optimal dosing frequency issue so that policy can be modified.
There is also a lack of consensus regarding the optimal duration of therapy in patients with EPTB, especially bone and joint TB, neurological TB; disseminated and miliary TB. While 6-months of treatment may be adequate in HIV-seronegative new patients with pulmonary TB and focal extrapulmonary TB, individual patients may require 9 to 12 months of treatment when TB meningitis is present given the serious risk of disability and mortality; and 9 months of treatment when bone and joint TB is also present. The efficacy and safety of erstwhile Category III (intermittent thrice-weekly rifampicin, isoniazid and pyrazinamide for 2 months, followed by rifampicin and isoniazid for 4 months) DOTS has been documented in the patients with uncomplicated small (<1500 ml) unilateral pleural effusion 202 , and peripheral lymph node TB
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.
Treatment of HIV-TB co-infection and X/MDR-TB
Treatment of active TB in patients co-infected with HIV requires careful consideration of drugdrug interactions between anti-TB and anti-retroviral drugs (Fig. 9 ) 204, 205 . Treatment of X/MDR-TB is expensive and time-consuming, and requires special facilities with adequate infrastructure, reliable, access to periodically accredited mycobacterial culture and sensitivity laboratories, medical, nursing and paramedical personnel trained in the management of X/ MDR-TB 
Key issues in TB treatment monitoring
Drug-drug interactions
Clinically significant interactions during anti-TB treatment should be carefully monitored as these may sometimes result in therapeutic failure or drug toxicity 207, 208 . This is particularly important in HIV-coinfected persons, the elderly and those with significant co-morbidities receiving treatment for the same (Box I) .
Drug induced hepatotoxicity (DIH)
Principles underlying evaluation of patients with DIH are listed in .
Immune reconstitution inflammatory syndrome (IRIS)
Paradoxical deterioration of lesions of TB in patients receiving anti-TB treatment has been known for a long time (218). Key developments in the understanding of IRIS are listed in Box I [219] [220] [221] [222] [223] [224] [225] [226] [227] [228] . Minor manifestations of IRIS can be managed with non-steroidal anti-inflammatory drugs (NSAIDS). Moderate-to-high dose corticosteroid treatment, sometimes for prolonged periods may be required for the treatment of paradoxical TB-IRIS and may be beneficial in TB-IRIS with CNS manifestations, tracheal compression due to lymphadenopathy, acute kidney injury and acute respiratory distress syndrome (ARDS) 218, 219 .
Treatment of LTBI
The WHO has stressed on the importance of interventions like ART provision and the three Is for HIV-TB coinfection, namely intensified TB case finding, infection control, and isoniazid preventive therapy (IPT), as part of prevention, care and treatment services 229 . The diagnosis and treatment of LTBI have been extensively reviewed recently 92 . It is necessary to rule out active TB disease before initiating treatment for LTBI. Important issues concerning LTBI and its treatment 92, [230] [231] [232] [233] [234] are listed in Box 2.
Control of TB
Global measures: India conceived the NTP and set an example to the world in the programmatic approach to TB control in 1962 197 . Since then several efforts have been undertaken globally to achieve control of TB and are summarized in Box III [235] [236] [237] [238] . These developments reflect the efforts towards achieving universal access to preventive, diagnostic and treatment services for all forms of TB.
As a result of the implementation of RNTCP, prevalence of all forms of TB has been brought down (from 338/100,000 population in 1990 to 249/100,000 population in 2009); TB mortality has also reduced (from >42/100,000 population in 1990 to 23/100,000 population in 2009) in India. The Phase II (2006 II ( -2012 of the RNTCP has achieved the set goals, the country is coursing towards achieving "universal access" for control of TB 197 and appears to be on track to achieve the TB related United Nations Millenium development Goals (UNMDG). Jointly with National AIDS Control Programme (NACP), RNTCP has developed "National framework of joint TB/HIV collaborative activities" that are being implemented in the country 197 .
Involvement of Medical Colleges in TB control
For the first time in the global history of TB control, Indian Medical Colleges were involved in the RNTCP. This unique experiment in the history of TB control has resulted in medical colleges providing diagnostic services (Designated Microscopy Centres), treatment (DOT Centres), referral for treatment, recording and reporting data, carrying out advocacy for RNTCP and conducting operational research on the RNTCP 238 .
Prevention
Even though the declining trends observed in the global burden of TB currently 37, [239] [240] [241] [242] , this trend seems insufficient to achieve the global target of elimination of TB in 2050 164 . Therefore, the need for other measures including infection control measures, newer or repurposed anti-TB drugs, newer and better vaccines for TB is pressing. • 207,208 isoniazid and the fluoroquinolones and the CYP450 isoform enzymes are responsible for many drug-drug interactions. The CYP3A4 isoform metabolizes many drugs, including PIs and NNRTIs. Rifampicin acts as a powerful inducer of CYP3A4, and also CYP2C19 and CYPD6; rifapentine is a less potent inducer; and rifabutin much less so. Isoniazid acts an inhibitor of CYP3A4. The CYP3A4 inhibitors have no effect on rifampicin metabolism, but increase the concentration of rifabutin 205 . Several drugs, such as, anticoagulants, anticonvulsants, antiinfectives, cardiovascular therapeutics, oral contraceptives, • glucocorticoids, immunosuppressants, psychotropics, sulphonylureas, and theophylline among others interact with rifampicin. Drug-drug interactions with isoniazid and anticonvulsants, benzodiazepines, theophylline, paracetamol etc., are known.
Drug-drug interactions
Drug-drug interactions usually involve rifampicin
Anti-TB drug-induced hepatotoxicity
In endemic areas, acute viral hepatitis may be a confounding factor in up to 15 per cent of patients suspected to have DIH due • to anti-TB drugs and should be ruled out as a cause of hepatic dysfunction 213, 214 . In comparison to patients with anti-TB DIH, patients with co-existent viral hepatitis have a later onset of acute hepatitis, large elevations in AST and ALT and a longer time for normalization of deranged liver functions 214 .
In patients with DIH, the potentially hepatotoxic drugs, rifampicin, isoniazid and pyrazinamide should be stopped
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. These patients should be treated with non-hepatotoxic drugs like ethambutol, streptomycin and a fluoroquinolone, till the liver functions normalize. In a recent randomized controlled trial from India 215 , 175 patients with a diagnosis of anti-TB DIH were randomized to receive one of three different pre-defined reintroduction regimens of anti-TB drugs and were evaluated prospectively. The recurrence rate of DIH was not significantly different between the groups receiving isoniazid, rifampicin, and pyrazinamide administered simultaneously at full dosage from day 1; and the groups receiving reintroduction regimens based on the ATS 216 and BTS guidelines 217 .
Immune reconstitution inflammatory syndrome
Paradoxical deterioration of lesions of TB in patients receiving anti-TB treatment has been known for a long time • 218 . IRIS has been recognized since the time of zidovudine monotherapy in the early 1990s and has described been in relation to infection, inflammatory disorders, autoimmune diseases and malignancy 219 . IRIS is characterized by paradoxical worsening of an existing infection or disease process or appearance of a new infection/disease process soon after initiation of therapy [220] [221] [222] .
TB-IRIS
A higher incidence of TB-IRIS has been reported in studies from West 
Airborne infection control measures
Recognizing the importance of airborne infection control and in view of the association of TB with HIV and the emergence of X/MDR-TB, guidelines have been issued for implementing the same by the WHO 239 and the RNTCP 240 as well. However, there is a wide gap between the needs and the actual implementation of these guidelines presently especially in the overcrowded government hospitals in India and other developing countries.
TB Vaccine
Till date the bacille Calmette-Guerin (BCG) vaccine is the only vaccine available for TB [241] [242] [243] [244] . Though BCG confers consistent protection against severe forms of TB, such as TB meningitis, disseminated and miliary TB in children in areas where TB is endemic its ability to protect against pulmonary TB has been found to be variable 245, 246 . New candidate vaccines for TB are in various stages of development and are listed in Table  VIII 241, 242, 247 . The summary of important changes in TB during the last 130 years since the time of Robert Koch in 1882 are listed in Table IX .
The Future
The search for newer and more efficient biomarkers for predicating a durable (non-relapsing) cure, indication of reactivation risk, prediction . Presently, the WHO recommends IPT for LTBI treatment at a daily dose of 5 mg/kg (maximum 300 mg) for at least 6 months and ideally for 9 months 230 . However, longer duration of IPT is associated with lesser compliance and it has been observed that if proper adherence is ensured, 12-month isoniazid therapy is more beneficial than 6-month isoniazid therapy 230 .
In the PREVENT TB clinical trial •
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, a open-label, randomized non-inferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) with 9 months of self-administered daily isoniazid (300 mg) alone in subjects at high risk for developing TB, use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniazid alone in preventing TB and had a higher treatment-completion rate.
Evidence-based guidelines for the treatment of LTBI in contacts of patients with MDR-TB are not available. An international • survey 234 evaluated TB programme practices, for managing MDR-TB contacts in countries with an MDR-TB prevalence of > 2% in new patients; 25 of the 35 countries meeting the survey criteria had responded. Of these, 19 countries usually or always evaluated contacts and treated LTBI; 10 reported having a guideline for managing MDR-TB contacts, 11 usually or always evaluated MDR-TB contacts, 9 treated LTBI. Some of the newer or repurposed anti-TB drugs are being tested for treating LTBI in MDR-TB contacts 235 , but it might take considerable time for the evidence thus generated to be translated into practice guidelines.
As of now, administering a combination regimen basing on the profile of the suspected isolate of • M. tuberculosis for 6-12 months seems to be a treatment option.
LTBI, latent tuberculosis infection; IPT, isoniazid preventive therapy; MDR-TB, multidrug-resistant tuberculosis Source: Refs 92, [230] [231] [232] [233] [234] [235] of eradication of LTBI; and prediction of vaccine efficacy 248, 249 , discovery of newer anti-TB drugs [250] [251] [252] [253] and development of newer additional candidate vaccines 254-257 is required to achieve the WHO and UNMDG goal of halting the incidence, prevalence and death rates associated with TB by 2015 and eliminating the disease altogether by 2050
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. Translation of newer innovative diagnostics for TB, such as, use of a 'handheld' nuclear magnetic resonance (NMR) apparatus capable of offering a 30-minute diagnosis of TB 258 , applications of nanotechnology 259, 260 to point-of-care diagnostic tests needs to be pursued.
Newer, repurposed drugs in pipeline
Presently, several newer or repurposed drugs are in pipeline in various stages of development as anti-TB drugs 252, 261 . Among the newer drugs, delamanid (OPC67683), bedaquiline (TMC207) and the nitroimidazole-oxazine PA-824 have been found to be active against both drug-sensitive and drugresistant strains. Bedaquiline (TMC207) has been approved for use by the United States-Food and Drug Administration (US-FDA). Their efficacy and safety have been demonstrated in MDR-TB patients in doubleblind, placebo controlled phase II clinical trials [262] [263] [264] . The Government of India is planning to regulate the introduction of these newer drugs in a systematic fashion by streamlining the conduct of clinical trials in India. Evidence is available that isoniazid-resistant clinical isolates of M. tuberculosis remain fully susceptible to the drug pyridomycin, a compound produced by Dactylosporangium fulvum with specific bactericidal activity against mycobacteria 265 . Pyridomycin merits further evaluation as an anti-TB drug.
Initiatives like the Critical Path to New TB Regimens (CPTR) involving several pharmaceutical companies and non-governmental organizations have been attempting to develop the newer drugs concomitantly in combination trials so that the best regimen and the shortest duration of time can be evolved 266 . Additional vaccine candidates are likely to enter clinical trials in future [254] [255] [256] [257] .
The last 70 years have witnessed an initial euphoria of emergence of drug treatment of TB that raised hopes and even signalled a likely 'elimination' of TB. Inspite of political commitment, global and national programmatic strategy to contain and control TB, eventual elimination of TB in near future appears to be a mirage as of now. The widespread occurrence of X/MDR-TB threatens to take us back to the era of untreatable TB. TB has come a long way, from despair and the status of an incurable malady, through a brief interlude of a curable disease to a scourge that is menacingly threatening the return to dark ages. Updated Global Plan to Stop TB 2011 -2015 Fourth edition of the "Guidelines for National Programmes" published ENGAGE-TB initiative developed by WHO. This initiative aims at integrating community-based activities to control TB in the ongoing work of such NGOs, aligned with national strategies and plans and supported by new operational guidance 2013
Post-2015 TB Strategy In February 2013, participants in a workshop convened by the WHO and the Stop TB Partnership have proposed a set of goals and targets to guide the global fight against TB after 2015. The overall aim was to achieve "zero TB deaths, zero TB disease and zero suffering". The following interim targets, namely, to reduce TB deaths and TB incidence rate by 75 and 40%, respectively by 2025 compared with 2015; and to attain a target of zero catastrophic expenditures for families affected by TB by 2025 were agreed upon TB, tuberculosis, IUATLD, International Union Against Tuberculosis and Lung Disease; UNAIDS, the Joint United Nations Programme on HIV/AIDS; FIND, Foundation for Innovative New Diagnostics; UNTAID, an an international drug purchase facility initiative financed with resources that would be both sustainable and predictable formed in 2006 by Brazil, Chile, France, Norway and the United Kingdom; AIDS, acquired immunodeficiency syndrome Source: Refs. 37, 236, 237 use, the march of the humankind towards the goal of TB elimination, i.e., reducing the annual incidence to less than 1 case/1,000,000 population by 2050 267 appears to be on course in the right direction. 
Epidemiological data
Systematization of global TB data collection has resulted in more reliable epidemiological data (including drug-resistant surveillance data) becoming available.
For the first time in the history of humankind, a fall in the absolute number of TB cases has been observed since 2006. But the march towards the eventual elimination of TB by 2050 appears to be still difficult to achieve.
Newer risk factors
Newer risk factors, such as, tobacco smoking, use of immunomodulator biologicals, diabetes mellitus being recognized.
Changing clinical picture of TB
HIV/AIDS epidemic, increased use of immunosuppressant medications result in more frequent occurrence of disseminated, miliary TB; cryptic, occult TB and atypical clinical presentations have resulted in diagnostic delays.
Imaging modalities
Availability of newer imaging modalities, such as, ultrasonography, CT, MRI, bone scan, PET-CT has facilitated more efficient clinical localization of lesions. Increasing use of image guided procurement of body fluids and tissues aids establishment of definitive diagnosis of TB.
Diagnostic methods
Advances in diagnostic modalities from the conventional smear and culture methods like liquid culture, rapid DST testing, molecular diagnostic methods being refined to arrive at a rapid diagnosis including DST profile. Global accredited diagnostic laboratory facility capacity building taken up. The rise and fall of serodiagnostic tests and more clarity on the diagnostic use of IGRAs emerges
Treatment
Global implementation of DOTS begins (1995); programmatic management of X/MDR-TB shapes up.
Vaccine
TB vaccine scenario that appeared bleak in the 1990s has seen the emergence of several newer TB vaccines that are in various phases of clinical trials.
The future
Newer/repurposed anti-TB drugs and vaccines are being tested. Bedaquiline (TMC207) has been approved for use by the USFDA. The Government of India is planning to regulate the introduction of these newer drugs in a systematic fashion after conducting phase 3 clinical trials at select sites in India.
CT, computed tomography; MRI, magnetic resonance imaging; PET-CT, positron emission tomography computed tomography; DST, drug-susceptibility testing; IGRAs, interferon-gamma release assays; X/MDR-TB, extensively drug-resistant and multidrug-resistant tuberculosis; BCG, bacille Calmette Guerin; USFDA, United States-Food and Drug Administration
